Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy.

Catalent today announced that it recently signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals, for LUPKYNIS™ (voclosporin), a drug to treat adult patients with lupus nephritis (LN).

Catalent has completed the acquisition of the manufacturing and packaging operations of Acorda Therapeutics, Inc., a developer of therapies to restore function and improve the lives of people with neurological disorders.

Catalent today announced the launch of its CosmoPod® Duo softgel capsule technology for the delivery of topical skin treatments.

Catalent today announced that it had signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.

Catalent and Decibel Therapeutics today announced they have signed an agreement for Catalent to provide Decibel with process and analytical development, and CGMP clinical manufacturing services, for Decibel’s lead investigational gene therapy product candidate, DB-OTO.

Catalent today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2021 in the United States.

Catalent has entered into a definitive agreement to acquire the manufacturing and packaging operations of Acorda Therapeutics, Inc. (Nasdaq: ACOR), a developer of therapies to restore function and improve the lives of people with neurological disorders.

Novan today announced an agreement with Catalent for the development of an intranasal formulation of berdazimer sodium for use in Novan’s COVID-19 program.